$MRK

Quotient Therapeutics and Merck partner on IBD drug discovery, with Quotient receiving $20M upfront and up to $2.2B in milestones.

Global ELISpot & FluoroSpot assay market to grow at 7.1% CAGR through 2031, driven by immunology research and personalized therapies.

Moderna's 69% YTD gain reflects mRNA vaccine upside, while Pfizer's 6.3% dividend offers stability as COVID revenues fade. Choice depends on risk appetite.

Biotech startup Unnatural Products secures $45M Series B funding led by The Venture Collective and inks $1.7B milestone deal with Novartis for oral peptide therapeutics.

Zostavax market set for sustained growth through 2035 driven by aging populations and expanded immunization programs, though tariff pressures spur manufacturing localization shifts.

RotaTeq rotavirus vaccine market expanding rapidly driven by rising immunization initiatives, increased disease cases, and manufacturing localization. North America leads; Asia-Pacific fastest-growing region.

Eli Lilly trades at expensive P/E of 44 with meager 0.6% dividend yield despite GLP-1 success. Merck offers better value at P/E 16 and 2.8% yield with 30+ year dividend track record.

Global cytokines market projected to grow from $95.32B (2025) to $174.53B (2032) at 9.02% CAGR, driven by manufacturing advances and strategic partnerships.

Tempus AI expands multi-year partnership with Merck to develop AI-driven precision medicine biomarkers, though stock declined 1.56% amid broader market weakness.

MXene market projected to grow from $0.05B to $0.29B by 2032 at 35.6% CAGR, driven by EV charging and aerospace demand.

Global antibiotics market to grow from USD 55.60B in 2025 to USD 70.64B by 2031 at 4.07% CAGR, driven by antimicrobial resistance and innovation.

Exelixis secures FDA approval for zanzalintinib and expands beyond cabozantinib with robust pipeline, posting 57.9% EPS growth while advancing multiple Phase 3 trials.

Colorectal cancer deaths surge among Americans under 50, becoming the leading cancer killer in this age group. An awareness campaign installs 27,000 blue flags on the National Mall.

Veeva Systems targets $6B revenue by 2030, doubling current business. Stock down 35% recently, but specialized platform and customer switching costs support long-term growth outlook.

Merck restructures commercial operations into two divisions ahead of Keytruda's 2028 patent expiration, aiming to accelerate growth from 20+ pipeline candidates.

Merck's RSV antibody Enflonsia shows positive Phase 3 results, supporting FDA expansion plans to protect more at-risk infants from respiratory syncytial virus infection.

Merck partners with Mayo Clinic to use AI and advanced analytics for drug discovery, focusing on inflammatory bowel disease, atopic dermatitis, and multiple sclerosis treatment development.

FDA grants J&J's Rybrevant Faspro breakthrough designation for HPV-negative head and neck cancer, potentially accelerating patient access to this new treatment option.

Investors anticipate 2026 market volatility, driving interest in defensive healthcare stocks. AbbVie and Merck offer stable dividends and historical resilience during downturns.

Eli Lilly acquires Orna Therapeutics for $2.4B to gain circular RNA gene therapy technology and autoimmune disease candidates, strengthening its pipeline.